(Q37956408)

25 August 2017

title

Liraglutide: a review of its use in the management of type 2 diabetes mellitus (English)

1 reference

25 August 2017

0 references

1 reference

1

Caroline M Perry

1 reference

25 August 2017

language of work or name

1 reference

1 December 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

71

1 reference

25 August 2017

issue

17

1 reference

25 August 2017

page(s)

2347-2373

1 reference

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Liraglutide: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label tr

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized,

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

The effects of glucagon-like peptide-1 on the beta cell

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Standards of medical care in diabetes--2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Trends in the epidemiology of the first attack of acute pancreatitis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Direct medical costs of acute pancreatitis hospitalizations in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

The incidence and case-fatality rates of acute biliary, alcoholic, and idiopathic pancreatitis in California, 1994-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Tria

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208110-000000000-00000

Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study.

21 January 2018

1 reference

12 December 2020

Effect of Three Different Injection Sites on the Pharmacokinetics of the Once-Daily Human GLP-1 Analogue Liraglutide

1 reference

12 December 2020

Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes

1 reference

12 December 2020

American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus

1 reference

12 December 2020

Mild renal impairment and the efficacy and safety of liraglutide.

1 reference

12 December 2020

Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents

1 reference

12 December 2020

Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin

1 reference

12 December 2020

Reductions in lipids and CV risk markers in patients with type 2 diabetes treated with liraglutide: a meta-analysis

1 reference

12 December 2020

Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting

1 reference

12 December 2020

The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen

1 reference

12 December 2020

10.2165/11208110-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

25 August 2017

1032195245

0 references

1 reference